Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 3/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CCKAR | P32238 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5269617 | 0.89 | MGLL (0.48) | MGLLALOX5PTGS2MALT1HPGD | |
| SCHEMBL5268500 | 0.87 | PTGS2 (0.48) | MGLLPTGS2HPGDMEN1MAPT | |
| SCHEMBL5269315 | 0.86 | CHRNA7 (0.38) | CHRNA7KDM1AMGLLALOX5GABRA1 | |
| SCHEMBL5269952 | 0.85 | MGLL (0.39) | MGLLALOX5PTGS2MALT1HPGD | |
| SCHEMBL5269005 | 0.84 | GABRA1 (0.51) | CHRNA7KDM1AALOX5GABRA1PTGS2 | |
| SCHEMBL5265857 | 0.83 | GABRA1 (0.41) | CHRNA7KDM1AMGLLALOX5GABRA1 | |
| SCHEMBL14529499 | 0.82 | ALOX5 (0.33) | ALOX5 | |
| SCHEMBL5267517 | 0.81 | RPA1 (0.46) | MEN1MAPTKMT2A | |
| SCHEMBL5271855 | 0.81 | GABRA1 (0.42) | CHRNA7KDM1AALOX5GABRA1HPGD | |
| SCHEMBL2916627 | 0.81 | ABL1 (0.38) | MGLLGABRA1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | CHRNA7 4207/4885KDM1A 1118/4885MGLL 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.